Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
103 Citations•2020•
Parakkal Deepak, Quazim A. Alayo, Aava Khatiwada
Real-world safety signals for tofacitinib are similar to those for clinical trials, with AEs reported from almost 16% of patients, support dose de-escalation after induction therapy, to reduce the risk of AEs.
Abstract
Real-world safety signals for tofacitinib are similar to those for clinical trials, with AEs reported from almost 16% of patients. HZ infection and VTE occurred in patients receiving 10 mg tofacitinib twice per day. These results support dose de-escalation after induction therapy, to reduce the risk of AEs.